Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Aaron Seth Kesselheim, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Aaron Kesselheim and Jessica Franklin.
Aaron Kesselheim
Connection Strength
7.444
Jessica Franklin
  1. Kesselheim AS, Hwang TJ, Franklin JM. Two decades of new drug development for central nervous system disorders. Nat Rev Drug Discov. 2015 Dec; 14(12):815-6.
    View in: PubMed
    Score: 0.701
  2. Kesselheim AS, Robertson CT, Siri K, Batra P, Franklin JM. Distributions of industry payments to Massachusetts physicians. N Engl J Med. 2013 May 30; 368(22):2049-52.
    View in: PubMed
    Score: 0.587
  3. Kesselheim AS, Robertson CT, Myers JA, Rose SL, Gillet V, Ross KM, Glynn RJ, Joffe S, Avorn J. A randomized study of how physicians interpret research funding disclosures. N Engl J Med. 2012 Sep 20; 367(12):1119-27.
    View in: PubMed
    Score: 0.281
  4. Kesselheim AS, Myers JA, Solomon DH, Winkelmayer WC, Levin R, Avorn J. The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS One. 2012; 7(2):e31894.
    View in: PubMed
    Score: 0.270
  5. Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA. 2011 Jun 08; 305(22):2320-6.
    View in: PubMed
    Score: 0.257
  6. Hey SP, Gyawali B, D'Andrea E, Kanagaraj M, Franklin JM, Kesselheim AS. A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises. J Natl Cancer Inst. 2020 04 01; 112(4):335-342.
    View in: PubMed
    Score: 0.237
  7. Feldman WB, Hey SP, Franklin JM, Kesselheim AS. Public Approval of Exception From Informed Consent in Emergency Clinical Trials: A Systematic Review of Community Consultation Surveys. JAMA Netw Open. 2019 07 03; 2(7):e197591.
    View in: PubMed
    Score: 0.225
  8. Hwang TJ, Bourgeois FT, Franklin JM, Kesselheim AS. Impact Of The Priority Review Voucher Program On Drug Development For Rare Pediatric Diseases. Health Aff (Millwood). 2019 02; 38(2):313-319.
    View in: PubMed
    Score: 0.219
  9. Fralick M, Avorn J, Franklin JM, Bartsch E, Abdurrob A, Kesselheim AS. Application and Impact of Run-In Studies for the Evaluation of Statin Efficacy and Safety. J Gen Intern Med. 2018 06; 33(6):792-794.
    View in: PubMed
    Score: 0.209
  10. Fralick M, Avorn J, Franklin JM, Abdurrob A, Kesselheim AS. Application and impact of run-in studies. J Gen Intern Med. 2018 05; 33(5):759-763.
    View in: PubMed
    Score: 0.205
  11. Jain N, Hwang T, Franklin JM, Kesselheim AS. Association of the Priority Review Voucher With Neglected Tropical Disease Drug and Vaccine Development. JAMA. 2017 07 25; 318(4):388-389.
    View in: PubMed
    Score: 0.197
  12. Hey SP, Franklin JM, Avorn J, Kesselheim AS. Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors. Circ Cardiovasc Qual Outcomes. 2017 Jun; 10(6).
    View in: PubMed
    Score: 0.195
  13. Hwang TJ, Franklin JM, Kesselheim AS. Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development. Clin Pharmacol Ther. 2017 Aug; 102(2):290-296.
    View in: PubMed
    Score: 0.195
  14. Wang B, Studdert DM, Sarpatwari A, Franklin JM, Landon J, Kesselheim AS. The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine. PLoS One. 2017; 12(4):e0175313.
    View in: PubMed
    Score: 0.193
  15. Kesselheim AS, Gagne JJ, Franklin JM, Eddings W, Fulchino LA, Campbell EG. Do patients trust the FDA?: a survey assessing how patients view the generic drug approval process. Pharmacoepidemiol Drug Saf. 2017 Jun; 26(6):694-701.
    View in: PubMed
    Score: 0.193
  16. Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, Kesselheim AS. Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. JAMA Intern Med. 2016 Dec 01; 176(12):1826-1833.
    View in: PubMed
    Score: 0.188
  17. Kesselheim AS, Eddings W, Raj T, Campbell EG, Franklin JM, Ross KM, Fulchino LA, Avorn J, Gagne JJ. Physicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug Approval. PLoS One. 2016; 11(10):e0163339.
    View in: PubMed
    Score: 0.187
  18. Yeh JS, Franklin JM, Kesselheim AS. Payments to Physicians, Prescribing Rates, and More Appropriate Conclusions-Reply. JAMA Intern Med. 2016 10 01; 176(10):1577.
    View in: PubMed
    Score: 0.186
  19. Hwang TJ, Lauffenburger JC, Franklin JM, Kesselheim AS. Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012. JACC Basic Transl Sci. 2016 Aug; 1(5):301-308.
    View in: PubMed
    Score: 0.185
  20. Hwang TJ, Sokolov E, Franklin JM, Kesselheim AS. Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort study. BMJ. 2016 Jun 28; 353:i3323.
    View in: PubMed
    Score: 0.183
  21. Kesselheim AS, Gagne JJ, Eddings W, Franklin JM, Ross KM, Fulchino LA, Campbell EG. Prevalence and Predictors of Generic Drug Skepticism Among Physicians: Results of a National Survey. JAMA Intern Med. 2016 06 01; 176(6):845-7.
    View in: PubMed
    Score: 0.182
  22. Yeh JS, Franklin JM, Avorn J, Landon J, Kesselheim AS. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts. JAMA Intern Med. 2016 06 01; 176(6):763-8.
    View in: PubMed
    Score: 0.182
  23. Kesselheim AS, Woloshin S, Eddings W, Franklin JM, Ross KM, Schwartz LM. Physicians' Knowledge About FDA Approval Standards and Perceptions of the "Breakthrough Therapy" Designation. JAMA. 2016 Apr 12; 315(14):1516-8.
    View in: PubMed
    Score: 0.180
  24. Wang B, Franklin JM, Eddings W, Landon J, Kesselheim AS. Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis. PLoS One. 2016; 11(3):e0152195.
    View in: PubMed
    Score: 0.180
  25. Kesselheim AS, Gagne JJ, Franklin JM, Eddings W, Fulchino LA, Avorn J, Campbell EG. Variations in Patients' Perceptions and Use of Generic Drugs: Results of a National Survey. J Gen Intern Med. 2016 06; 31(6):609-14.
    View in: PubMed
    Score: 0.178
  26. Yeh JS, Austad KE, Franklin JM, Chimonas S, Campbell EG, Avorn J, Kesselheim AS. Medical Schools' Industry Interaction Policies Not Associated With Trainees' Self-Reported Behavior as Residents: Results of a National Survey. J Grad Med Educ. 2015 Dec; 7(4):595-602.
    View in: PubMed
    Score: 0.176
  27. Kesselheim AS, Wang B, Franklin JM, Darrow JJ. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. BMJ. 2015 Sep 23; 351:h4633.
    View in: PubMed
    Score: 0.173
  28. Kesselheim AS, Franklin JM, Kim SC, Seeger JD, Solomon DH. Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population. J Gen Intern Med. 2015 Nov; 30(11):1633-8.
    View in: PubMed
    Score: 0.168
  29. Yeh JS, Austad KE, Franklin JM, Chimonas S, Campbell EG, Avorn J, Kesselheim AS. Association of medical students' reports of interactions with the pharmaceutical and medical device industries and medical school policies and characteristics: a cross-sectional study. PLoS Med. 2014 Oct; 11(10):e1001743.
    View in: PubMed
    Score: 0.162
  30. Austad KE, Avorn J, Franklin JM, Campbell EG, Kesselheim AS. Association of marketing interactions with medical trainees' knowledge about evidence-based prescribing: results from a national survey. JAMA Intern Med. 2014 Aug; 174(8):1283-90.
    View in: PubMed
    Score: 0.160
  31. Austad KE, Avorn J, Franklin JM, Kesselheim AS. Physician trainees' interactions with the pharmaceutical industry. J Gen Intern Med. 2013 Oct; 28(10):1267.
    View in: PubMed
    Score: 0.151
  32. Austad KE, Avorn J, Franklin JM, Kowal MK, Campbell EG, Kesselheim AS. Changing interactions between physician trainees and the pharmaceutical industry: a national survey. J Gen Intern Med. 2013 Aug; 28(8):1064-71.
    View in: PubMed
    Score: 0.149
  33. Kesselheim AS, Franklin JM, Avorn J, Duke JD. Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs. BMJ Qual Saf. 2013 Sep; 22(9):727-34.
    View in: PubMed
    Score: 0.147
  34. Dave CV, Patorno E, Franklin JM, Huybrechts K, Sarpatwari A, Kesselheim AS, Bateman BT. Impact of State Laws Restricting Opioid Duration on Characteristics of New Opioid Prescriptions. J Gen Intern Med. 2019 11; 34(11):2339-2341.
    View in: PubMed
    Score: 0.058
  35. Mundkur ML, Franklin J, Huybrechts KF, Fischer MA, Kesselheim AS, Linder JA, Landon J, Patorno E. Changes in Outpatient Use of Antibiotics by Adults in the United States, 2006-2015. Drug Saf. 2018 12; 41(12):1333-1342.
    View in: PubMed
    Score: 0.054
  36. Hwang TJ, Franklin JM, Chen CT, Lauffenburger JC, Gyawali B, Kesselheim AS, Darrow JJ. Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines. J Clin Oncol. 2018 06 20; 36(18):1805-1812.
    View in: PubMed
    Score: 0.052
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.